IGF-1 DES vs Ipamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
IGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profileIpamorelin
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery.
Full profile| IGF-1 DES | Ipamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 | NNC 26-0161, Ipamorelin acetate |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout | 100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout) |
| Administration | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) | Subcutaneous injection, Intramuscular injection |
| Key side effects | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses | Water retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient) |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: IGF-1 DES is research-stage, while Ipamorelin is investigational (in trials).
- Administration: IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect); Ipamorelin — Subcutaneous injection, Intramuscular injection.
- Frequency: IGF-1 DES is typically 1–2x daily, preferably post-workout; Ipamorelin is 1–3x daily (typically pre-sleep and/or pre-workout).
- Research depth: this profile cites 2 sources for IGF-1 DES vs 3 for Ipamorelin.
How each works
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
Ipamorelin
Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.